The increased risk of thromboembolism in cancer

The increased risk of thromboembolism in cancer

00:52 |

Related Videos

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

5:11

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

3:08

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

The future of CLL treatment: aiming for long-lasting remission

1:42

The future of CLL treatment: aiming for long-lasting remission

Frontline treatment for CLL: the changing paradigm

1:31

Frontline treatment for CLL: the changing paradigm

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

5:21

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

Challenges in risk stratifying LR-MDS: insights into genetic upstaging and early transplant

1:13

Challenges in risk stratifying LR-MDS: insights into genetic upstaging and early transplant

Factors to consider when selecting patients with multiple myeloma for treatment with bispecifics

0:42

Factors to consider when selecting patients with multiple myeloma for treatment with bispecifics

Early detection and interception across hematological cancers

0:44

Early detection and interception across hematological cancers

The use of golcadomide in combination with R-CHOP for the treatment of aggressive B-cell lymphomas

1:38

The use of golcadomide in combination with R-CHOP for the treatment of aggressive B-cell lymphomas

Trials of interest in newly diagnosed myeloma presented at IMS 2024

3:48

Trials of interest in newly diagnosed myeloma presented at IMS 2024

Advice for physicians when managing bispecific antibody treatment for patients with myeloma

0:47

Advice for physicians when managing bispecific antibody treatment for patients with myeloma

The use of outpatient cilta-cel in the treatment of multiple myeloma

1:36

The use of outpatient cilta-cel in the treatment of multiple myeloma

The tests that are needed to make a definitive diagnosis of CLL

2:59

The tests that are needed to make a definitive diagnosis of CLL

New approaches to treating transplant-ineligible multiple myeloma: triplets and quadruplets

3:26

New approaches to treating transplant-ineligible multiple myeloma: triplets and quadruplets

A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib

2:55

A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib

Personalizing the timing of SCT in patients with myelofibrosis

2:13

Personalizing the timing of SCT in patients with myelofibrosis

The new criteria for defining high-risk multiple myeloma

3:00

The new criteria for defining high-risk multiple myeloma

Key challenges in treating patients with t(11;14) multiple myeloma with BCL2 inhibitors

2:17

Key challenges in treating patients with t(11;14) multiple myeloma with BCL2 inhibitors

CLL highlights from ASH 2023: the FLAIR study

1:53

CLL highlights from ASH 2023: the FLAIR study

Real-world safety and efficacy of talquetamab for the treatment of R/R myeloma

1:47

Real-world safety and efficacy of talquetamab for the treatment of R/R myeloma